Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of di...

Full description

Bibliographic Details
Main Authors: Mackey, J., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W., Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in
Format: Journal Article
Published: Oxford University Press 2016
Online Access:http://hdl.handle.net/20.500.11937/58543

Internet

http://hdl.handle.net/20.500.11937/58543

Similar Items